Gates Foundation extends funding for AN2 Therapeutics-GSK TB drug research collaboration
ANTX•AN2 Therapeutics received extended Gates Foundation funding for its tuberculosis research and development collaboration with GSK. The funding supports development of boron-based leucyl-tRNA synthetase inhibitors as potential TB treatments.
1. Extended research funding
AN2 Therapeutics received extended Gates Foundation funding for its tuberculosis research and development collaboration with GSK. The funding supports development of boron-based leucyl-tRNA synthetase inhibitors as potential new TB treatments.
